Nasus Pharma awards CEO 210,000 stock options

Available on EDGAR 11/13/2026 - 07:35 PM EST Accepted by SEC EDGAR 11/13/2026 - 07:35 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Nasus Pharma Ltd (NSRX) reported a 210,000-option award to Chief Executive Officer Brendan P. O'Grady, part of his compensation package approved by shareholders on October 8, 2026. The options were granted July 27, 2026: 70,000 vest July 27, 2027, and the remaining options vest in eight quarterly installments of 17,500 beginning October 27, 2027. The three 70,000-option tranches have exercise prices of $3.50, $4.25 and $5.00 per ordinary share, subject to a floor of fair market value on the grant date.

Insider Trade Summary

Grant/Award: 210,000 shares

Grant/Award 1 txn

Insider O'Grady Brendan P.

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Share options (right to buy) F2, F1	210,000	--	--

Holdings After Transaction: Share options (right to buy) — 210,000 options (Direct)

Holdings Before and After: Share options (right to buy), 0 to 210,000 options (Direct)

Footnotes (2)

1. F1. Options to purchase 210,000 ordinary shares of the Issuer, no par value ("Ordinary Shares"), were granted on July 27, 2026, with one-third of such options, representing 70,000 options, vesting on July 27, 2027, and the remaining two-thirds vesting in eight equal quarterly installments of 17,500 options, beginning on October 27, 2027. The foregoing options are part of the reporting person's compensation package as the Chief Executive Officer of the Issuer, which was approved by the Issuer's shareholders on October 8, 2026.
2. F2. Of the 210,000 options reported herein, the first one-third, representing 70,000 options, will be exercisable at $3.50 per Ordinary Share, the second one-third, representing 70,000 options, will be exercisable at $4.25 per Ordinary Share, and the final one-third, representing 70,000 options, will be exercisable at $5.00 per Ordinary Share; provided that the exercise price of an option may not be less than the Fair Market Value of an Ordinary Share, as defined pursuant to the Issuer's 2019 Incentive Option Plan, including, without limitation, the Sub-Plan for U.S. Persons, on the grant date.

Key Figures

Options awarded: 210,000 options to purchase ordinary shares First vesting tranche: 70,000 options Quarterly vesting installment: 17,500 options +3 more

6 metrics

Options awarded 210,000 options to purchase ordinary shares Part of the CEO compensation package approved October 8, 2026

First vesting tranche 70,000 options Vesting date: July 27, 2027

Quarterly vesting installment 17,500 options Eight quarterly installments beginning October 27, 2027

Exercise price, first tranche $3.50 per ordinary share 70,000-option tranche

Exercise price, second tranche $4.25 per ordinary share 70,000-option tranche

Exercise price, final tranche $5.00 per ordinary share 70,000-option tranche

Key Terms

Fair Market Value, 2019 Incentive Option Plan, vesting

3 terms

Fair Market Value financial

"may not be less than the Fair Market Value of an Ordinary Share"

The price a willing buyer and a willing seller would agree on for an asset or security when neither is under pressure and both have access to the same information. Think of it as the market’s neutral estimate of what something is worth, like the price two neighbors would settle on for a car after comparing similar listings. Investors care because fair market value guides buying and selling decisions, tax reporting, portfolio valuation, and how accurately company assets are reflected in financial statements.

2019 Incentive Option Plan technical

"as defined pursuant to the Issuer's 2019 Incentive Option Plan"

vesting technical

"remaining two-thirds vesting in eight equal quarterly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many options did Nasus Pharma (NSRX) award its CEO?

Chief Executive Officer Brendan P. O'Grady received options to purchase 210,000 ordinary shares. The options were granted July 27, 2026, and the compensation package was approved by shareholders on October 8, 2026.

What are the vesting dates and exercise prices for O'Grady's NSRX options?

One-third, or 70,000 options, vests July 27, 2027; the remaining two-thirds vest in eight equal quarterly installments of 17,500 beginning October 27, 2027. The three 70,000-option tranches have exercise prices of $3.50, $4.25 and $5.00 per ordinary share, respectively, subject to a minimum equal to fair market value on the grant date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Grady Brendan P.

(Last) (First) (Middle)

P.O. BOX 284

(Street)

TEL-AVIV-YAFO 6100201

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nasus Pharma Ltd [ NSRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share options (right to buy)	(2)	10/08/2026		A		210,000		07/27/2027(1)	07/27/2036	Ordinary Shares	210,000	(2)	210,000	D

Explanation of Responses:

1. Options to purchase 210,000 ordinary shares of the Issuer, no par value ("Ordinary Shares"), were granted on July 27, 2026, with one-third of such options, representing 70,000 options, vesting on July 27, 2027, and the remaining two-thirds vesting in eight equal quarterly installments of 17,500 options, beginning on October 27, 2027. The foregoing options are part of the reporting person's compensation package as the Chief Executive Officer of the Issuer, which was approved by the Issuer's shareholders on October 8, 2026.

2. Of the 210,000 options reported herein, the first one-third, representing 70,000 options, will be exercisable at $3.50 per Ordinary Share, the second one-third, representing 70,000 options, will be exercisable at $4.25 per Ordinary Share, and the final one-third, representing 70,000 options, will be exercisable at $5.00 per Ordinary Share; provided that the exercise price of an option may not be less than the Fair Market Value of an Ordinary Share, as defined pursuant to the Issuer's 2019 Incentive Option Plan, including, without limitation, the Sub-Plan for U.S. Persons, on the grant date.

	/s/ Brendan O'Grady	11/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)